Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia

Arsenic trioxide (ATO) mediates PML-RARA (promyelocytic leukemia–retinoic acid receptor-α) oncoprotein degradation via the proteasome pathway and this degradation appears to be critical for achieving cure in acute promyeloytic leukemia (APL). We have previously demonstrated significant micro-environ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganesan, S, Alex, A A, Chendamarai, E, Balasundaram, N, Palani, H K, David, S, Kulkarni, U, Aiyaz, M, Mugasimangalam, R, Korula, A, Abraham, A, Srivastava, A, Padua, R A, Chomienne, C, George, B, Balasubramanian, P, Mathews, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097069/
https://www.ncbi.nlm.nih.gov/pubmed/27560113
http://dx.doi.org/10.1038/leu.2016.227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097069/
https://www.ncbi.nlm.nih.gov/pubmed/27560113
http://dx.doi.org/10.1038/leu.2016.227

Ejemplares similares